ELCC 2019 | Challenges in using ALK inhibitors

Nicolas Girard

Here, Nicolas Girard, MD, PhD, of Claude Bernard University, Lyon, France, discusses the problems with molecularly guided sequencing of ALK (EML4-ALK fusion gene) inhibitors. Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Girard explains the problems with current methods for screening mutations and the lack of a specific mechanism for identification.

Share this video